Clinical presentation and course after COVID-19 symptoms
| Total (N=113) | |
| Symptoms at clinical diagnosis, n(%) | |
| Fever>37.2°C | 74 (65.5) |
| Cough | 64 (56.6) |
| Dyspnoea | 30 (26.6) |
| Fatigue | 19 (16.8) |
| Confusion | 14 (12.4) |
| Diarrhoea | 13 (11.5) |
| Muscle pain | 9 (8) |
| Thoracic pain | 5 (4.4) |
| Anosmia and dysgeusia | 4 (3.5) |
| Other | 4 (3.5) |
| Chest X-ray or thorax CT scan, n(%) | |
| No | 12 (10.7) |
| Yes, normal | 39 (34.8) |
| Yes, ground-glass opacities | 58 (51.8%) |
| Yes, lobar infiltrates+ground-glass opacities | 3 (2.7) |
| Missing | 1 |
| Respiratory support, n(%) | |
| No | 57 (50.4) |
| O2 support | 28 (24.8) |
| Non-invasive ventilation | 13 (11.5) |
| Invasive mechanical ventilation | 15 (13.3) |
| AD, n (%) | |
| No | 75 (66.4) |
| Yes | 34 (30.1) |
| Yes, unrelated to COVID-19 | 4 (3.5) |
| ACLF, n (%) | |
| No ACLF | 93 (82.3) |
| ACLF grade 1a | 0 (0) |
| ACLF grade 1b | 2 (1.8) |
| ACLF grade 2 | 3 (2.7) |
| ACLF grade 3a | 3 (2.7) |
| Unrelated to COVID-19 | 1 of 3 |
| ACLF grade 3b | 12 (10.6) |
| Unrelated to COVID-19 | 2 of 12 |
| CLIF-C ACLF score | |
| Median (IQR) | 60.82 (11–42) |
| Renal replacement therapy, n (%) | 9 (8) |
| Vasoactive drugs (norepinephrine), n (%) | 16 (14.3) |
| Myocarditis, n (%) | 3 (2.7) |
| Bilirubin (mg/dL): peak value | |
| Median (IQR) | 3.2 (1.4–10.1) |
| INR: peak value | |
| Median (IQR) | 1.5 (1.2–2) |
| Creatinine (mg/dL): peak value | |
| Median (IQR) | 1.1 (0.8–1.6) |
| MELD score: peak value | |
| Median (IQR) | 18 (13–25) |
| COVID-19 therapy, n (%) | |
| None | 64 (56.6) |
| Low-molecular weight heparin | 29 (25.7) |
| OH-chloroquine | 16 (14.2 |
| Azythromicin | 14 (12.4) |
| High-dose steroids | 7 (6.2) |
| Lopinavir/ritonavir | 5 (4.4) |
| Tocilizumab | 5 (4.4) |
| Remdesevir | 4 (3.5) |
| Other | 2 (1.8) |
| Outcome, n (%) | |
| Alive | 75 (66.4%) |
| Dead | 37 (32.7%) |
| Death after LT | 1 (0.9%) |
| Time between symptoms and last follow-up (days) | |
| Median (IQR) | 55 (27–183) |
| Cause of death, N (%) | |
| Respiratory failure | 10 (27) |
| Liver failure+respiratory failure | 20 (54.1) |
| Liver failure without respiratory failure | 4 (10.8) |
| Other causes+respiratory failure | 3 (8.1) |
| Patients having received an LT, n (%) | 26 (23) |
| Time between symptoms and LT (days), median (IQR) | 78.5 (44–102) |
ACLF, acute-on-chronic liver failure; AD, acute decompensation; CLIF-C, Chronic Liver Failure Consortium; LT, liver transplantation; MELD, Model for End-stage Liver Disease.